B lymphoma Moloney murine leukemia virus insertion region 1: An oncogenic mediator in prostate cancer.
- Author:
Qipeng LIU
1
;
Qiaqia LI
1
;
Sen ZHU
1
;
Yang YI
1
;
Qi CAO
1
Author Information
- Publication Type:Review
- Keywords: B lymphoma Moloney murine leukemia virus insertion region 1; oncogene; polycomb repressive complex 1; prostate cancer
- MeSH: Animals; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell/genetics*; Male; Mice; Moloney murine leukemia virus/genetics*; Mutagenesis, Insertional/genetics*; Polycomb Repressive Complex 1/genetics*; Prostatic Neoplasms/genetics*
- From: Asian Journal of Andrology 2019;21(3):224-232
- CountryChina
- Language:English
- Abstract: B lymphoma Moloney murine leukemia virus insertion region 1 (BMI1), a core member of polycomb repressive complex 1 (PRC1), has been intensely investigated in the field of cancer epigenetics for decades. Widely known as a critical regulator in cellular physiology, BMI1 is essential in self-renewal and differentiation in different lineages of stem cells. BMI1 also plays a significant role in cancer etiology for its involvement in pathological progress such as epithelial-mesenchymal transition (EMT) and cancer stem cell maintenance, propagation, and differentiation. Importantly, overexpression of BMI1 is predictive for drug resistance, tumor recurrence, and eventual therapy failure of various cancer subtypes, which renders the pharmacological targeting at BMI1 as a novel and promising therapeutic approach. The study on prostate cancer, a prevalent hormone-related cancer among men, has promoted enormous research advancements in cancer genetics and epigenetics. This review summarizes the role of BMI1 as an oncogenic and epigenetic regulator in tumor initiation, progression, and relapse of prostate cancer.
